CYP19A1 and breast cancer: This has been shown by the results of previous studies of neoadjuvant therapy with aromatase inhibitors in postmenopausal breast cancer patients.4, 7 In the present study, switching nonresponders from exemestane monotherapy to exemestane‐based chemotherapy did not increase the rate of conversion from mastectomy to BCS.